A Feasibility Study of Durvalumab + Tremelimumab in Resected Non-Small Cell Lung Cancer (NSCLC) Patients with Detectable Circulating Tumor DNA after Adjuvant Treatment
||Male and Female Patients
|U.S. Govt. ID:
||Research Nurse Navigator: 212-342-5162 / firstname.lastname@example.org
The purpose of this research study is to see how effective durvalumab andtremelimumab is in patients with early stage non-small cell lung cancer (NSCLC). A a special blood test will be done to see if subjects have circulating tumor DNA (ctDNA) in their blood. ctDNA are pieces of genetic material shed from the tumor cells that can be detected in the blood, which can suggests that there are left over cancer cells in the body or that the cancer is growing back. The purpose of this study is to evaluate the possibility and safety of giving investigational treatment with durvalumab and tremelimumab once the ctDNA is detected but before there is any evidence of cancer seen on imaging. Durvalumab and tremelimumab are a type of immunotherapy, which helps to stimulate the immune system.
This study is closed
Catherine Shu, MD
|Have you been diagnosed with non-small cell lung cancer (NSCLC)?
|Do you have a life expectancy of at least 12 weeks?